TDC
SUPN icon

Thompson Davis & Co’s Supernus Pharmaceuticals SUPN Stock Holding History

Thompson Davis & Co’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-125
Closed -$7K – 784
2018
Q2 		$7K Buy
+125
New +$6.47K 0.02% 483

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Thompson Davis & Co's SUPN Position: Q3 2018 in Review

Thompson Davis & Co sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 125 shares — an estimated $7K sold.

Thompson Davis & Co first reported a position in SUPN in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

  • Thompson Davis & Co reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Supernus Pharmaceuticals shares in Q3 2018, an estimated $7K.
  • Thompson Davis & Co first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Thompson Davis & Co's Supernus Pharmaceuticals position peaked at $7K in Q2 2018.
  • 288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.